Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
Nocturnal Hypoxia and Sleep Apnea Associated With Late-Onset Epilepsy
Published: June 18th 2024 | Updated: June 19th 2024A recent study showed a significant association between sleep apnea, additional sleep characteristics, and late-onset epilepsy in older adults, even after adjusting for comorbidities.
Newly Formed Clinical Advisory Board United in Potential of SAT-3247 for Duchenne Muscular Dystrophy
Published: June 13th 2024 | Updated: June 14th 2024Satellos Bioscience has established a clinical advisory board to aid in developing their lead drug candidate SAT-3247, an oral small molecule therapy for Duchenne muscular dystrophy.
Diagnostic Code Aids in Predicting Isolated REM Sleep Behavior Disorder in Outpatient Setting
Published: June 6th 2024 | Updated: June 6th 2024A recent study showed that patients with isolated REM sleep behavior disorder had a high risk of neurodegenerative parkinsonian disorders or dementia based on electronic health records.
Where Are We: Development of Gene and Cell Approaches for Parkinson Disease
Published: June 5th 2024 | Updated: June 6th 2024According to recent studies and the latest insights provided by experts, early developments in gene and cell therapies show promise for patients living with Parkinson disease, but challenges remain.
Deep Learning Model Predicts Cognitive Status With High Accuracy From Sleep EEG Data
June 5th 2024Researchers presented an innovative multi-task learning paradigm that leveraged deep learning, night sleep EEG data, sleep stage labels, and covariates to simultaneously predict cognitive performance in an older patient cohort.
Age-Dependent Risk for Neurodegenerative Disorder Identified in Obstructive Sleep Apnea
June 4th 2024In a clinical cohort study, approximately 89% of patients with obstructive sleep apnea classified as “Probably-normal” or “Likely-normal" in assessment of sleep biomarker-based neurodegenerative disorder risk.
FDA Approves Dose Expansion of Catalyst's Amifampridine for Lambert-Eaton Myasthenic Syndrome
Published: June 3rd 2024 | Updated: June 7th 2024The FDA approval of the increased maximum daily dose for amifampridine offers clinicians and patients greater flexibility in treatment regimens for the management of Lambert-Eaton myasthenic syndrome.
Exploring the Association Between Brain Lesions and Takotsubo Syndrome
May 21st 2024Frederic Schaper, MD, PhD, an instructor in neurology at Brigham and Women's Hospital, discussed the complex interplay between brain lesions and takotsubo syndrome, a heart condition caused by physical and emotional triggers.